Dawar Meenakshi, Patrick David M, Bigham Mark, Cook Darrel, Krajden Mel, Ng Helen
First Nations and Inuit Health Branch, Medical Programs, Pacific Region, Health Canada, Vancouver, BC.
CMAJ. 2003 Mar 18;168(6):703-4.
Countries with a low risk of hepatitis B (HB) lack data on the effectiveness of universal HB vaccination programs for children. British Columbia began a program in 1992, offering HB vaccination to 11 year olds. We conducted an anonymous, unlinked serologic survey 7 years later, analyzing a random sample of specimens (n = 1215) from women aged 15-44 years who had undergone antenatal rubella testing. Among those aged 15-19 years inclusive there was no evidence of chronic HB (HB surface antigen), the proportion with evidence of acute HB (anti-HB core antibody) was only 0.6% (compared with 6.5% for the entire sample), and evidence of protective immunity was strong: the prevalence of anti-HB surface antibody (anti-HBs) was 79.1% (compared with 41.4% for the entire sample) and the geometric mean titre was 34.9 IU/mL (compared with 0.6-0.8 IU/mL for the older groups [p < 0.001]).
乙肝（HB）低风险国家缺乏针对儿童的普遍乙肝疫苗接种计划有效性的数据。不列颠哥伦比亚省于1992年启动了一项计划，为11岁儿童提供乙肝疫苗接种。7年后，我们进行了一项匿名、无关联的血清学调查，分析了15至44岁接受产前风疹检测的女性的随机样本（n = 1215）。在15至19岁（含15岁和19岁）的人群中，没有慢性乙肝（乙肝表面抗原）的证据，有急性乙肝证据（抗乙肝核心抗体）的比例仅为0.6%（整个样本为6.5%），且保护性免疫证据充分：抗乙肝表面抗体（抗-HBs）的患病率为79.1%（整个样本为41.4%），几何平均滴度为34.9 IU/mL（老年组为0.6 - 0.8 IU/mL [p < 0.001]）。
